Search

Your search keyword '"Battistella, M."' showing total 1,538 results
Start Over Author "Battistella, M."
1,538 results on '"Battistella, M."'

152. Essai de phase 2 multicentrique évaluant le pembrolizumab dans la maladie de Kaposi classique ou endémique

Author

Delyon, J., primary, Resche-Rigon, M., additional, Renaud, M., additional, Le Goff, J., additional, Dalle, S., additional, Heidelberger, V., additional, Da Meda, L., additional, Allain, V., additional, Toullec, L., additional, Mourah, S., additional, Carcelain, G., additional, Caillat-Zucman, S., additional, Battistella, M., additional, and Lebbe, C., additional

Published
2020
Full Text
View/download PDF

154. Résultats à long terme des patients avec dermatofibrosarcome de Darier-Ferrand localement avancé (DFSP-LA) traités par inhibiteurs de tyrosine kinase suivis d’une exérèse chirurgicale complète

Author

Beaziz, J., primary, Battistella, M., additional, Delyon, J., additional, Farges, C., additional, Marco, O., additional, Pages, C., additional, Le Maignan, C., additional, Basset-Seguin, N., additional, Walter-Petrich, A., additional, Kérob, D., additional, Lebbé, C., additional, and Baroudjian, B., additional

Published
2020
Full Text
View/download PDF

156. Myelodysplasia cutis

Author

Delaleu, J., primary, Battistella, M., additional, Bouaziz, J.-D., additional, Laurent, C., additional, Fenaux, P., additional, Jachiet, M., additional, Zuelgaray, E., additional, Rathana, K., additional, Vignon-Pennamen, M.-D., additional, de Masson, A., additional, and Bagot, M., additional

Published
2020
Full Text
View/download PDF

159. Caractérisation clinique biologique et moléculaire de l’acropulpite dans le lupus érythémateux systémique : une nouvelle entité associée à une signature interféron élevée

Author

Sonigo, G.G., primary, Cassius, C., additional, Battistella, M., additional, Le Buanec, H., additional, Bagot, M., additional, Saussine, A., additional, De Masson, A., additional, Lehmann Che, J., additional, Jachiet, M., additional, and Bouaziz, J.-D., additional

Published
2020
Full Text
View/download PDF

161. Impact des algorithmes du Groupe Français d’Étude des Lymphomes Cutanés sur le diagnostic anatomopathologique des lymphoproliférations cutanées

Author

Menguy, S., primary, Mansour, Y., additional, Augereau, O., additional, Ortonne, N., additional, Balme, B., additional, Battistella, M., additional, Lamant, L., additional, Beltzung, F., additional, Szablewski, V., additional, Gaulard, P., additional, Bagot, M., additional, Beylot-Barry, M., additional, and Vergier, B., additional

Published
2020
Full Text
View/download PDF

162. Déficit persistant des cellules MAIT au cours de la dermatomyosite

Author

Cassius, C., primary, Branchtein, M., additional, Battistella, M., additional, Lepelletier, C., additional, Jachiet, M., additional, De Masson, A., additional, Frulholtz, L., additional, Chasset, F., additional, Amoura, Z., additional, Mathian, A., additional, Monfort, J.-B., additional, Bachmeyer, C., additional, Cordoliani, F., additional, Bengoufa, D., additional, Bensussan, A., additional, Bagot, M., additional, Le Buanec, H., additional, and Bouaziz, J.-D., additional

Published
2020
Full Text
View/download PDF

165. Activation endothéliale associée aux ANCA IgA au cours des lésions de lésions acrales pendant l’épidémie de COVID-19

Author

Frumholtz, L., primary, Bouaziz, J.-D., additional, Battistella, M., additional, Bengoufa, D., additional, Hadjadj, J., additional, Jaume, L., additional, Gendron, N., additional, Schwartz, O., additional, Yatim, N., additional, Bachelez, H., additional, Bagot, M., additional, Rieux-Laucat, F., additional, Le Goff, J., additional, Smadja, D., additional, and Cassius, C., additional

Published
2020
Full Text
View/download PDF

167. 1077MO PD1 blockade with pembrolizumab in classic and endemic Kaposi sarcoma: A multicenter phase II study

Author

Delyon, J., primary, Resche-Rigon, M., additional, Renaud, M., additional, Le Goff, J., additional, Dalle, S., additional, Heidelberger, V., additional, Da Meda, L., additional, Allain, V., additional, Toullec, L., additional, Carcelain, G., additional, Mourah, S., additional, Caillat-Zucman, S., additional, Battistella, M., additional, and Lebbé, C., additional

Published
2020
Full Text
View/download PDF

169. Diagnosis and treatment of Kaposi's sarcoma: European consensus-based interdisciplinary guideline (EDF/EADO/EORTC)

Author

Lebbe C, Garbe C, Stratigos AJ, Harwood C, Peris K, Marmol VD, Malvehy J, Zalaudek I, Hoeller C, Dummer R, Forsea AM, Kandolf-Sekulovic L, Olah J, Arenberger P, Bylaite-Bucinskiene M, Vieira R, Middleton M, Levy A, Eggermont AM, Battistella M, Spano JP, Grob JJ, Pages C, European Dermatology Forum (EDF), the European Association of Dermato-Oncology (EADO) and the European Organisation for Research and Treatment of Cancer (EORTC)., Lebbe, C, Garbe, C, Stratigos, Aj, Harwood, C, Peris, K, Marmol, Vd, Malvehy, J, Zalaudek, I, Hoeller, C, Dummer, R, Forsea, Am, Kandolf-Sekulovic, L, Olah, J, Arenberger, P, Bylaite-Bucinskiene, M, Vieira, R, Middleton, M, Levy, A, Eggermont, Am, Battistella, M, Spano, Jp, Grob, Jj, Pages, C, European Dermatology Forum (EDF), the European Association of Dermato-Oncology (EADO) and the European Organisation for Research and Treatment of Cancer (EORTC)., University of Zurich, and Lebbe, Celeste

Subjects
0301 basic medicine, Oncology, Male, Cancer Research, medicine.medical_specialty, Electrochemotherapy, Consensus, EADO, medicine.medical_treatment, 610 Medicine & health, Disease, Kaposi, Guideline, 03 medical and health sciences, 0302 clinical medicine, Immune reconstitution inflammatory syndrome, Risk Factors, Internal medicine, medicine, Humans, 1306 Cancer Research, Kaposi's sarcoma, Sarcoma, Kaposi, business.industry, EDF, EORTC, Sarcoma, 10177 Dermatology Clinic, medicine.disease, Radiation therapy, Europe, 030104 developmental biology, Lymphatic system, 030220 oncology & carcinogenesis, 2730 Oncology, Female, business, Settore MED/35 - MALATTIE CUTANEE E VENEREE
Abstract

Kaposi's sarcoma (KS) is a multifocal neoplasm of lymphatic endothelium-derived cells infected with human herpesvirus 8. Four clinical subtypes are distinguished: the classic, the endemic, the epidemic subtype in HIV positive patients and the iatrogenic subtype. The diagnosis is primarily based on clinical features and confirmation by histology with immunohistochemistry. Cutaneous distribution and severity, mucosal, nodal and visceral involvement depend on the type of KS with in general indolent behaviour and chronic evolution in the classic subtype and the more severe forms in iatrogenic or epidemic subtypes. Management should aim at achieving disease control. For localised lesions, several local therapies have been developed without randomised trial comparisons. Radiotherapy, intralesional chemotherapies and electrochemotherapy have high response rates. Topical treatments-imiquimod or topical 9-cis-retinoid acid-can also be used. Systemic treatments are reserved for locally aggressive extensive and disseminated KS: the recommended first-line agents are pegylated liposomal doxorubicin (PLD) and paclitaxel. In CKS, PLD or low-dose interferon-alfa are the recommended first-line agents in younger patients. In AIDS-related KS, combination antiretroviral therapy is the first treatment option; specific systemic treatment is needed only in case of extensive disease and in the prevention and treatment of immune reconstitution inflammatory syndrome. In post-transplant KS, tapering down immunosuppressive therapy and switching to mammalian target of rapamycin (m-TOR) inhibitors are used. Follow-up schedules for patients with KS disease depend on aggressiveness of the disease.

Published
2019

173. Vismodegib resistant mutations are not selected in multifocal relapses of locally advanced basal cell carcinoma after vismodegib discontinuation

Author

Ighilahriz, M, Benfodda, M, Sharpe, H, Soufir, N, Mourah, S, Dumaz, N, Battistella, M, Savina, A, Bouquet, F, Nikolaev, S, Basset-Seguin, N, Basset-Seguin, N [0000-0002-9136-1244], and Apollo - University of Cambridge Repository

Subjects
Skin Neoplasms, Carcinoma, Basal Cell, Drug Resistance, Neoplasm, Pyridines, Mutation, Humans, Anilides, Neoplasm Recurrence, Local
Abstract

Hedgehog pathway inhibitors (HPI) inactivating SMO 1, have become first line treatment for patients with locally advanced BCC (laBCC). HPI safety and efficacy have been shown in clinical trials2,3. Nevertheless, common adverse events lead to treatment discontinuation.

Published
2019
Full Text
View/download PDF

175. Type I interferon response and vascular alteration in chilblain‐like lesions during the COVID‐19 outbreak*.

Author

Frumholtz, L., Bouaziz, J.‐D., Battistella, M., Hadjadj, J., Chocron, R., Bengoufa, D., Le Buanec, H., Barnabei, L., Meynier, S., Schwartz, O., Grzelak, L., Smith, N., Charbit, B., Duffy, D., Yatim, N., Calugareanu, A., Philippe, A., Guerin, C.L., Joly, B., and Siguret, V.

Subjects
TYPE I interferons, ENDOTHELIUM diseases, ANTINEUTROPHIL cytoplasmic antibodies, COVID-19, SYMPTOMS, COVID-19 pandemic
Abstract

Summary: Background: The outbreak of chilblain‐like lesions (CLL) during the COVID‐19 pandemic has been reported extensively, potentially related to SARS‐CoV‐2 infection, yet its underlying pathophysiology is unclear. Objectives: To study skin and blood endothelial and immune system activation in CLL in comparison with healthy controls and seasonal chilblains (SC), defined as cold‐induced sporadic chilblains occurring during 2015 and 2019 with exclusion of chilblain lupus. Methods: This observational study was conducted during 9–16 April 2020 at Saint‐Louis Hospital, Paris, France. All patients referred with CLL seen during this period of the COVID‐19 pandemic were included in this study. We excluded patients with a history of chilblains or chilblain lupus. Fifty patients were included. Results: Histological patterns were similar and transcriptomic signatures overlapped in both the CLL and SC groups, with type I interferon polarization and a cytotoxic–natural killer gene signature. CLL were characterized by higher IgA tissue deposition and more significant transcriptomic activation of complement and angiogenesis factors compared with SC. We observed in CLL a systemic immune response associated with IgA antineutrophil cytoplasmic antibodies in 73% of patients, and elevated type I interferon blood signature in comparison with healthy controls. Finally, using blood biomarkers related to endothelial dysfunction and activation, and to angiogenesis or endothelial progenitor cell mobilization, we confirmed endothelial dysfunction in CLL. Conclusions: Our findings support an activation loop in the skin in CLL associated with endothelial alteration and immune infiltration of cytotoxic and type I IFN‐polarized cells leading to clinical manifestations. What is already known about this topic?Chilblain‐like lesions have been reported during the COVID‐19 pandemic.They are associated with systemic type I interferon polarization, but the precise pathophysiology is still unclear. What does this study add?We demonstrate cutaneous and systemic immune activation and vascular alteration.Histological patterns were similar and transcriptomic signatures overlapped in chilblain‐like lesions and a comparator group with seasonal chilblains.A systemic immune response was associated with high prevalence of IgA antineutrophil cytoplasmic antibodies and an elevated type I interferon signature.We confirmed endothelial dysfunction in chilblain‐like lesions. What is the translational message?Chilblain‐like lesions and seasonal chilblains seem to share a common pathophysiology.The strong type I interferon response can be explained by a viral trigger.Similar endothelial dysfunctions have been described during mild COVID‐19.Local or systemic anti‐inflammatory treatment could reverse cutaneous manifestations. Linked Comment: S.M. Pilkington and R.E.B. Watson. Br J Dermatol 2021; 185:1090–1091. Plain language summary available online [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

180. The PROCLIPI international registry of early‐stage mycosis fungoides identifies substantial diagnostic delay in most patients

Author

Scarisbrick, J.J., primary, Quaglino, P., additional, Prince, H.M., additional, Papadavid, E., additional, Hodak, E., additional, Bagot, M., additional, Servitje, O., additional, Berti, E., additional, Ortiz‐Romero, P., additional, Stadler, R., additional, Patsatsi, A., additional, Knobler, R., additional, Guenova, E., additional, Child, F., additional, Whittaker, S., additional, Nikolaou, V., additional, Tomasini, C., additional, Amitay, I., additional, Prag Naveh, H., additional, Ram‐Wolff, C., additional, Battistella, M, additional, Alberti‐Violetti, S., additional, Stranzenbach, R., additional, Gargallo, V., additional, Muniesa, C., additional, Koletsa, T., additional, Jonak, C., additional, Porkert, S., additional, Mitteldorf, C., additional, Estrach, T., additional, Combalia, A., additional, Marschalko, M., additional, Csomor, J., additional, Szepesi, A., additional, Cozzio, A., additional, Dummer, R., additional, Pimpinelli, N., additional, Grandi, V., additional, Beylot‐Barry, M., additional, Pham‐Ledard, A., additional, Wobser, M., additional, Geissinger, E., additional, Wehkamp, U., additional, Weichenthal, M., additional, Cowan, R., additional, Parry, E., additional, Harris, J., additional, Wachsmuth, R., additional, Turner, D., additional, Bates, A., additional, Healy, E., additional, Trautinger, F., additional, Latzka, J., additional, Yoo, J., additional, Vydianath, B., additional, Amel‐Kashipaz, R., additional, Marinos, L., additional, Oikonomidi, A., additional, Stratigos, A., additional, Vignon‐Pennamen, M.‐D., additional, Battistella, M., additional, Climent, F., additional, Gonzalez‐Barca, E., additional, Georgiou, E., additional, Senetta, R., additional, Zinzani, P., additional, Vakeva, L., additional, Ranki, A., additional, Busschots, A.‐M., additional, Hauben, E., additional, Bervoets, A., additional, Woei‐A‐Jin, F.J.S.H., additional, Matin, R., additional, Collins, G., additional, Weatherhead, S., additional, Frew, J., additional, Bayne, M., additional, Dunnill, G., additional, McKay, P., additional, Arumainathan, A., additional, Azurdia, R., additional, Benstead, K., additional, Twigger, R., additional, Rieger, K., additional, Brown, R., additional, Sanches, J.A., additional, Miyashiro, D., additional, Akilov, O., additional, McCann, S., additional, Sahi, H., additional, Damasco, F.M., additional, Querfeld, C., additional, Folkes, A., additional, Bur, C., additional, Klemke, C.‐D., additional, Enz, P., additional, Pujol, R., additional, Quint, K., additional, Geskin, L., additional, Hong, E., additional, Evison, F., additional, Vermeer, M., additional, Cerroni, L., additional, Kempf, W., additional, Kim, Y., additional, and Willemze, R., additional

Published
2018
Full Text
View/download PDF

181. The realization of the High Voltage Short Gap Test Facilty

Author

Lotto L., De Lorenzi A., Pilan N., Tiso A., Rossetto F., Romanato L., Battistella M., Maniero M., Barbato P., and Cervaro V.

Subjects
MITICA, Megavolt Iter Injector and Concept Advancement, HVSGTF, High Voltage Short Gap Test Facilty
Abstract

Voltage holding in vacuum is one of the most critical issues for the experiment MITICA (Megavolt ITer Injector & Concept Advancement), aimed at realizing of the 40 A - 1 MegaVolt prototype of the ITER HNB at the Consorzio RFX in Padova. For this reason, boosting the R&D on this specific problem has been identified as a priority to attain the success of the MITICA experiment. To this purpose, a dedicated High Voltage Test Facility to test electrodes separated by Short vacuum Gaps (HVSGTF) has been realized, aiming at studying the fundamental mechanism related to Fowler-Nordheim electron emission which are at the basis of the voltage breakdown. HVSGTF is designed to carry out experiments up to 100 kVdc with metal and non metal electrodes in high vacuum and separated by gaps in the range from 0.1 to 2 mm. This configuration allows the study of field emission from real surface, in the framework of the recent theoretical model (Breakdown-Induced by Rupture of Dielectric - BIRD model) elaborated at the Consorzio RFX, with high electrode electric field but with low voltage, so that the total voltage effect results almost suppressed. This contribution describes the technical details of the facility, the architecture of the control system, and the results of the commissioning.

Published
2019

182. Diagnosis and treatment of Kaposi's sarcoma: European consensus-based interdisciplinary guideline (EDF/EADO/EORTC)

Author

Lebbe, C. Garbe, C. Stratigos, A.J. Harwood, C. Peris, K. Marmol, V.D. Malvehy, J. Zalaudek, I. Hoeller, C. Dummer, R. Forsea, A.M. Kandolf-Sekulovic, L. Olah, J. Arenberger, P. Bylaite-Bucinskiene, M. Vieira, R. Middleton, M. Levy, A. Eggermont, A.M. Battistella, M. Spano, J.P. Grob, J.J. Pages, C. the European Dermatology Forum (EDF), the European Association of Dermato-Oncology (EADO)and the European Organisation for Research Treatment of Cancer (EORTC)

Abstract

Kaposi's sarcoma (KS)is a multifocal neoplasm of lymphatic endothelium-derived cells infected with human herpesvirus 8. Four clinical subtypes are distinguished: the classic, the endemic, the epidemic subtype in HIV positive patients and the iatrogenic subtype. The diagnosis is primarily based on clinical features and confirmation by histology with immunohistochemistry. Cutaneous distribution and severity, mucosal, nodal and visceral involvement depend on the type of KS with in general indolent behaviour and chronic evolution in the classic subtype and the more severe forms in iatrogenic or epidemic subtypes. Management should aim at achieving disease control. For localised lesions, several local therapies have been developed without randomised trial comparisons. Radiotherapy, intralesional chemotherapies and electrochemotherapy have high response rates. Topical treatments—imiquimod or topical 9-cis-retinoid acid—can also be used. Systemic treatments are reserved for locally aggressive extensive and disseminated KS: the recommended first-line agents are pegylated liposomal doxorubicin (PLD)and paclitaxel. In CKS, PLD or low-dose interferon-alfa are the recommended first-line agents in younger patients. In AIDS-related KS, combination antiretroviral therapy is the first treatment option; specific systemic treatment is needed only in case of extensive disease and in the prevention and treatment of immune reconstitution inflammatory syndrome. In post-transplant KS, tapering down immunosuppressive therapy and switching to mammalian target of rapamycin (m-TOR)inhibitors are used. Follow-up schedules for patients with KS disease depend on aggressiveness of the disease. © 2019 Elsevier Ltd

Published
2019

183. RF R&D activity report

Author

Recchia M., Maistrello A., Gasparini F., Ferrari F., Jain P., Rossetto F., Battistella M., Baseggio L., Caon M., Cervaro V., Friso D., Ghiraldelli R., Lotto L., Pasqualotto R., Rigoni A., Rizzieri R., Zella D., and Zucchetti S.

Subjects
RF R&D, neutral beam test facility, NBTF
Abstract

In 2018 the activity under the RF R&D task 5.8 of the 2018 Work Programme was addressed to the characterization of the voltage hold off capability of different RF driver mockups on the High Voltage Radio Frequency Test Facility (HVRFTF). Particular effort was addressed to review the facility layout and to improve its high voltage RF circuit in terms of impedance matching, frequency tuning capability, RF power available and protection against fault in circuit components. Furthermore the set of diagnostic tools was improved with a plasma light sensor and a camera. Their respective signals and images, along with the gas pressure signal (already available as diagnostic since 2016) are sent to the data acquisition system.

Published
2019

184. Manufacturing Design of SPIDER/MITICA Safety Items

Author

Grando L. and Battistella M.

Subjects
Neutral Beam Test Facility, ITER, NBTF, PRIMA, F4E-OFC, NBTF Control and Data Acquisition Interlock and Safety
Abstract

This document is the manufacturing design of the safety items included in the specific contract F4E-OFC-280-03-It does not include the manufacturing design of surveillance camera system that is managed through a different document (F4E_D_2FHBGN v2.0). The document is aligned with the contractual deviation SDR#:60775 approved on 9 Dec. 2019.

Published
2019

185. Vacuum High Voltage Holding: DC Experiments and modelling

Author

Pilan N., Barbato P., Baseggio L., Battistella M., Bernardi M., Carraro M., Cavazzana R., Cervaro V., Cinetto P., De Lorenzi A., Fincato M., Fontana C., Friso D., Gobbo G., Grosso B., Laterza L., Lotto L., Manduchi G., Maniero M., Muraro A., Martines E., Mc Cormack O., Migliorato L., Moretti M., Nobili P., Patton T., Pesavento G., Pino F., Polato S., Rigoni A., Rigamonti D., Rizzieri R., Romanato L., Rossetto F., Spada E., Spagnolo S., Taliercio C., Tiso A., vignando M., and Zuin M.

Subjects
F4E-RFX, Vacuum High Voltage Holding, Neutral Beam Test Facility, HVPTF, High Voltage Padova Test Facility, NBTF
Abstract

This report describes the activities carried out within the subtask T5.7 of the Work Programme WP2019 at the High Voltage Padova Test Facility HVPTF and on the new High Voltage Short Gap Test Facility HVSGTF. The activities mainly consisted in: 1) Test of two electrodes with double-polarity configurations (Common Mode Voltage tests). 2) Test of electropolished electrodes 3) Tests with cathode covered by a thick alumina cap 4) Removal of dust deposited inside the vacuum vessel before starting the vacuum system: 5) Tests with specific shaped electrodes designed to understand the effect of the mutual exchange of charged particles between electrodes are still in progress 6) Tests of Non Evaporable Getter (NEG) pumps at high voltage in high vacuum are still in progress 7) Ordinary Maintenance of the vacuum pump system 8) Tests in HVSGTF to measure the Fowler-Nordheim emission current from stainless steel electrodes. The activities mentioned in points #5 and #6 are still in progress and will be completed next year. Concerning the other experiments, the main outcomes can be reported as follows: 1) CMV tests showed that the main microdischarge activity of the electrodes appears to be related to phenomena involving only a single power supply unit and the vacuum chamber, rather than the two electrodes under test 2) Test of electropolished electrodes, tests with cathode covered by a thick alumina cap and Removal of dust deposited inside the vacuum vessel did not indicate significant improvements of voltage holding 3) The measurement of the Fowler-Nordheim emission current from stainless steel electrodes showed a behaviour much more complex than expected and their analysis is in progress.

Published
2019

186. WP2019 MITICA SAFETY ACTIVITY REPORT

Author

Battistella M., Grando L., Breda M., Moressa M., Barbato P., Carraro M., Baseggio L., Cinetto P., Caon M., Zucchetti S., Ghiraldelli R., Rizzieri R., and Vignando M.

Subjects
MITICA, Neutral Beam Test Facility, NBTF, F4E-RFX-PMS
Abstract

The MITICA Central Safety System (MITICA CSS) implements a set of important protection functions related to personnel health and safety, both during and outside the operation of the MITICA test bed, providing continuous monitoring of potentially dangerous events, automated protection actions, and logging of events and data relevant for safety of people. The Technical Specification for the call for tender of the supply of the MITICA CSS was drafted in 2017 (ref. RFX_MITICA_TS_041), but some important details were still to be defined, also depending on the status of the procurement of plant systems interfacing with MITICA CSS and according to the experience acquired with SPIDER CSS installation. This document is intended to be the report of the main activities related to MITICA safety carried out in 2019, in order to better define the aspects needed to pass from the MITICA CSS "Draft" to the "Detailed" Techinical Specification.

Published
2019

187. MANUFACTURING DESIGNOF SPIDER SAFETY SYSTEM - RADIOPROTECTION INSTRUMENTATION

Author

Battistella M., Carraro M., and Grando L.

Subjects
SPIDER Control & Data Acquisition Interlock and Safety, F4E-RFX, Neutral Beam Test Facility, NBTF, SPIDER CODAS, F4E-OFC, SPIDER
Abstract

This document is intended as the Manufacturing Design required in Task Order #03of F4E-OFC-280 Framework Contract for the part related to radioprotection instrumentation(OPTION #02)installed in NBTF buildings.

Published
2019

192. First operation in SPIDER and the path to complete MITICA

Author

Serianni, G., primary, Toigo, V., additional, Bigi, M., additional, Boldrin, M., additional, Chitarin, G., additional, Dal Bello, S., additional, Grando, L., additional, Luchetta, A., additional, Marcuzzi, D., additional, Pasqualotto, R., additional, Pomaro, N., additional, Zaccaria, P., additional, Zanotto, L., additional, Agostinetti, P., additional, Agostini, M., additional, Antoni, V., additional, Aprile, D., additional, Barbisan, M., additional, Battistella, M., additional, Brombin, M., additional, Canton, A., additional, Cavazzana, R., additional, Dalla Palma, M., additional, Dan, M., additional, Delogu, R., additional, De Lorenzi, A., additional, De Muri, M., additional, Denizeau, S., additional, Fadone, M., additional, Fellin, F., additional, Ferro, A., additional, Gaio, E., additional, Gambetta, G., additional, Gasparini, F., additional, Gnesotto, F., additional, Jain, P., additional, Maistrello, A., additional, Manduchi, G., additional, Manfrin, S., additional, Marchiori, G., additional, Marconato, N., additional, Moresco, M., additional, Patton, T., additional, Pavei, M., additional, Peruzzo, S., additional, Pilan, N., additional, Pimazzoni, A., additional, Piovan, R., additional, Poggi, C., additional, Recchia, M., additional, Rigoni, A., additional, Rizzolo, A., additional, Rostagni, G., additional, Sartori, E., additional, Siragusa, M., additional, Sonato, P., additional, Spada, E., additional, Spagnolo, S., additional, Spolaore, M., additional, Taliercio, C., additional, Tinti, P., additional, Ugoletti, M., additional, Valente, M., additional, Zamengo, A., additional, Zaniol, B., additional, Zaupa, M., additional, Cavenago, M., additional, Boilson, D., additional, Rotti, C., additional, Veltri, P., additional, Chareyre, J., additional, Decamps, H., additional, Dremel, M., additional, Graceffa, J., additional, Geli, F., additional, Schunke, B., additional, Svensson, L., additional, Urbani, M., additional, Bonicelli, T., additional, Agarici, G., additional, Garbuglia, A., additional, Masiello, A., additional, Paolucci, F., additional, Simon, M., additional, Bailly-Maitre, L., additional, Bragulat, E., additional, Gomez, G., additional, Gutierrez, D., additional, Labate, C., additional, Mico, G., additional, Moreno, J. F., additional, Pilard, V., additional, Kouzmenko, G., additional, Rousseau, A., additional, Chakraborty, A., additional, Baruah, U., additional, Patel, H., additional, Singh, N. P., additional, Patel, A., additional, Dhola, H., additional, Raval, B., additional, Cristofaro, S., additional, Fantz, U., additional, Heinemann, B., additional, Kraus, W., additional, Kashiwagi, M., additional, and Tobari, H., additional

Published
2020
Full Text
View/download PDF

198. Efficacité et tolérance de l’association brentuximab védotin et bendamustine dans les lymphomes T cutanés de stade avancé

Author

Dumont, M., primary, Ram-Wolff, C., additional, Roelens, M., additional, Brice, P., additional, Peffault de la Tour, R., additional, Battistella, M., additional, Madelaine, I., additional, Julie, D., additional, Herms, F., additional, Bouaziz, J.-D., additional, Moins-Teisserenc, H., additional, Lebbé, C., additional, De Masson, A., additional, and Bagot, M., additional

Published
2019
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results